Advances in the treatment of myocardial infarction

Research output: Contribution to journalArticlepeer-review


A recent meta analysis of common treatments for patients with myocardial infarction has shown that mortality and recurrent myocardial infarction can be reduced with certain interventions (Table 7). Reductions in mortality have been noted with acute, short-term treatments such as thrombolytic therapy, beta blockers, nitrates, anticoagulants, and aspirin. Long-term interventions which reduce mortality include the beta blockers and antiplatelet drugs. Lidocaine and calcium channel blockers given acutely have not been shown to reduce mortality, and the same is true for long-term calcium channel blocker therapy. Reinfarction may be reduced with intravenous beta blockers and aspirin, and in non-Q-wave infarction. Long-term benefit for reinfarction, has been demonstrated with aspirin, diltiazem, and beta blockers. Several new approaches such as free-radical scavengers and thromboxane synthesis inhibitors or receptor blockers will likely add to the armamentarium for AMI in the future as our understanding of the appropriate use of available agents expands over the coming years.

Original languageEnglish (US)
Pages (from-to)43-58
Number of pages16
JournalAmerican Journal of Pharmacy and the Sciences Supporting Public Health
StatePublished - Dec 1 1989

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Advances in the treatment of myocardial infarction'. Together they form a unique fingerprint.

Cite this